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Background: Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept
study (NCT01303172), explored safety and tolerability of IMM-101 (heat-killed Mycobacterium obuense; NCTC 13365) with
gemcitabine (GEM) in advanced pancreatic ductal adenocarcinoma.
Methods: Patients were randomised (2 : 1) to IMM-101 (10mgml l intradermally)þGEM (1000mgm 2 intravenously; n¼ 75), or
GEM alone (n¼ 35). Safety was assessed on frequency and incidence of adverse events (AEs). Overall survival (OS), progression-
free survival (PFS) and overall response rate (ORR) were collected.
Results: IMM-101 was well tolerated with a similar rate of AE and serious adverse event reporting in both groups after allowance for
exposure. Median OS in the intent-to-treat population was 6.7 months for IMM-101þGEM v 5.6 months for GEM; while not significant,
the hazard ratio (HR) numerically favoured IMM-101þGEM (HR, 0.68 (95% CI, 0.44–1.04, P¼ 0.074). In a pre-defined metastatic subgroup
(84%), OS was significantly improved from 4.4 to 7.0 months in favour of IMM-101þGEM (HR, 0.54, 95% CI 0.33–0.87, P¼ 0.01).
Conclusions: IMM-101 with GEM was as safe and well tolerated as GEM alone, and there was a suggestion of a beneficial effect on
survival in patients with metastatic disease. This warrants further evaluation in an adequately powered confirmatory study.
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Only 18% of patients with advanced pancreatic ductal adenocarci-
noma (PDAC) remain alive at 1 year, and 4% at 5 years (Hidalgo
et al, 2015). Survival for metastatic disease is more dismal. Real-
world studies report the overall median survival from diagnosis to
be 4.6 months; in patients with metastatic cancer the median
survival ranges between 2.8 and 5.7 months (Carrato et al, 2015).
When IMAGE-1 was set up, gemcitabine (GEM) was the
standard of care for advanced PDAC (Burris et al, 1997; Network;
Seufferlein et al, 2012) and at that time it was widely used as the
comparator arm in clinical trials for this disease. Over the past
5 years, FOLFIRINOX, as well as GEMþ nab-paclitaxel (Abrax-
ane), have entered the clinical arena, mainly for patients with a
good performance status because they increase toxicity signifi-
cantly (Conroy et al, 2011; Von Hoff et al, 2013). The combination
of nab-paclitaxelþGEM demonstrated clinical benefit in the first-
line treatment of pancreatic cancer (Von Hoff et al, 2013) and was
subsequently approved for the first-line treatment of metastatic
adenocarcinoma of the pancreas. However, its use in clinical
practice has experienced setbacks in Europe, for instance, in 2015,
NICE (the National Institute for Health and Care Excellence) did
not approve the use of nab-paclitaxel in combination with GEM,
but it maintained the recommendation for GEM as the first-line
treatment of advanced pancreatic cancer (NICE, 2001; NICE,
2015). The lack of reimbursement for nab-paclitaxel also limits use
of this combination in the Benelux countries, Ireland and Eastern
Europe. Despite the recent advances of FOLFIRINOX and nab-
paclitaxelþGEM in the treatment of pancreatic cancer, the
majority of pancreatic cancer patients (76%) do not receive either
of these regimens as first-line treatment (Braiteh et al, 2016).
Therefore, an unmet need remains for therapies that confer
meaningful survival advantages without additional toxicity.
Immunotherapy is effective in treating many cancers (Tempero
et al, 2012), although success in PDAC is limited (Gunturu et al,
2013; Pico de Coana et al, 2015). Extended survival after second-
line treatment with the therapeutic vaccine GVAX and CRS-207
(live-attenuated Listeria monocytogenes) has been reported after
the treatment with low-dose cyclophosphamide (Le et al, 2015).
IMM-101 is a systemic immune modulator containing heat-
killed Mycobacterium obuense (NCTC 13365). Results from in vivo
and ex vivo non-clinical studies suggest that IMM-101 modulates
the innate and adaptive immune systems, in response to cancer.
IMM-101 acts on cells of the innate immune system, such as gd
T-cells, granulocytes, and antigen-presenting cells, by interaction
with a number of receptors (PAMPs-PRR; Fowler et al, 2011)
(Bazzi et al, 2015). Activation of these cells is known to have a
cytotoxic effect against tumours. Furthermore, it is proposed that
IMM-101 restores Type-1 response, influences cytotoxic cell
immune function and may downregulate Type 2 response. This
is of significance because pancreatic cancer has been associated
with a Th2 bias (Wormann et al, 2014).
In a phase I clinical study, IMM-101 was safe and well tolerated
at the three escalating doses used in patients with melanoma
(Stebbing et al, 2012). Therefore, IMAGE-1 was designed as a
proof of concept (POC), phase II study primarily to explore the
safety and tolerability of IMM-101 in combination with GEM vs
GEM alone as first-line treatment in advanced PDAC. In addition,
the study would provide some insight into the potential effects of
treatment on the clinical signs and symptoms of disease including
overall survival (OS), progressive-free survival (PFS) and overall
response rate (ORR).
MATERIALS AND METHODS
Study design and patients. This open-label, phase II trial was
conducted at 20 institutions in 5 countries (Cyprus, Ireland, Italy,
Spain, UK). Eligible patients were age X18 years, had confirmed
inoperable PDAC (with or without metastatic disease), measurable
lesions at X1 site not previously irradiated, and WHO perfor-
mance status (PS) 0–2. Other inclusion criteria included serum
albumin X26 g l 6, C-reactive protein (CRP) p70mg l 1, and
life expectancy43 months from randomisation. Exclusion criteria
included prior PDAC chemotherapy, radiotherapy within 6 weeks
of screening and chronic use of corticosteroids within 2 weeks of
first study drug. The study was undertaken in compliance with the
Declaration of Helsinki Principles and applicable local–regional
regulations. The study protocol, the patient information leaflet and
informed consent form were reviewed and approved by an
Independent Ethics Committee/Institutional Review Board. All
patients provided written informed consent. Patients were
randomly assigned in a 2 : 1 ratio to receive IMM-101þGEM or
GEM alone by Interactive Response Technology. Randomisation
was stratified according to disease extent and WHO PS, by
computer generated block randomisation methods.
Procedures. In both groups, GEM was administered intravenously
at 1000mgm 2 over 30min weekly for 3 weeks out of 4, with dose
reductions allowed for toxicity. IMM-101 (0.1ml of 10mgml 1
suspension) was administered by intradermal injection into the
skin overlying the deltoid muscle with the arm alternated for each
dose. This dose of IMM-101 was previously shown to be safe and
well tolerated in patients with melanoma (Stebbing et al, 2012).
Dosing delays or half doses were allowed if skin reaction was
unacceptable. IMM-101 was administered every 2 weeks for three
doses followed by 4 weeks rest, then every 2 weeks for a further
three doses. Subsequent doses were administered every 4 weeks; the
first IMM-101 dose was administered 2 weeks before the first dose
of GEM. Upon disease progression or toxicity to GEM, second-line
chemotherapy of the investigator’s choice was allowed.
Maximum treatment duration was 12 cycles. All patients who
completed the study (from both treatment groups) were able to enter
a long-term follow-up study in which all would receive IMM-101.
Assessments. Adverse events (AEs) were reported at each visit
according to National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.0 (DCTD, NHI, DHHS,
Bethesda, MD, USA; http://cstep.cancer.gov/reporting/ctc.html).
To assess the impact on toxicity of the time on study treatment, the
rates of patients per month on study reporting at least one AE or at
least one serious AE (SAE) were calculated. Injection site reactions
to IMM-101 were recorded at each visit and included assessments
of pain, induration, wet drainage, erythema, and tenderness as well
as any impact on daily activities. Tumour response was determined
by investigator assessment at baseline, weeks 13, 25, 37, and 48,
and as clinically indicated according to RECIST v1.1 (Brussels,
Belgium; http://www.eortc.be/recist). Complete (CR) or partial
responses (PR), and stable disease beyond 3 months were
confirmed by a second radiologist.
Statistical analysis. As an exploratory, phase II, POC study with
safety and tolerability assessment as the primary endpoint, the trial
was not formally sized to test a specific efficacy hypothesis. A target
of 90 patients (on a 2 : 1 allocation basis) was considered feasible
and sufficient to address the primary endpoint. This number of
patients is broadly in line with the size of other randomised, phase
II trials in oncology, and was considered sufficient to provide
insight into the potential efficacy of IMM-101 on additional
endpoints including OS, PFS, and ORR.
Safety assessment was based on frequency and incidence of AEs
using the safety analysis set of all patients who received study drug.
OS and PFS outcomes were displayed as Kaplan–Meier curves for
the intent-to-treat (ITT) analysis set and for the metastatic and
locally advanced subgroups (only a selection of Kaplan-Meier
curves will be displayed in this paper). Median survival estimates as
well as 95% confidence intervals (CI) were reported for each group.
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OS and PFS differences were tested by two-sided log-rank tests.
Cox proportional hazard (PH) regression models were used to
estimate hazard ratios (HR) with 95% CI. Data were censored if
patients remained alive (OS), or had no recorded progression (PFS)
at the time of analysis, or were lost to follow-up. Survival times
were calculated from the date of randomisation until death. PFS
was defined as the interval between randomisation and radiological
and/or clinical progression or death. ORR was defined as a
complete or partial response. Disease stabilisation included those
patients with a response and also stable disease X3 months.
To assess the potential influence of baseline characteristics on
survival and PFS outcomes, an exploratory multivariate stepwise
analysis (Cox PH regression model) was conducted for factors
reported as prognostic for survival in PDAC (carbohydrate antigen
19.9 (CA19.9), carcinoembryonic antigen (CEA), lactate dehydro-
genase (LDH), CRP, neutrophil-lymphocyte ratio (NLR), total
bilirubin, age, and PS) (Bilici, 2014; Haas et al, 2013) alongside
treatment group for the ITT and metastatic subgroup.
RESULTS
Patients and treatment. Between July 2011 and August 2013, 110
patients were enrolled and randomised (Figure 1). The ITT
analysis included all randomised patients. Five patients in the
IMM-101þGEM group and one patient in the GEM group
remained alive and were censored for OS at the last point of follow
up. A further six patients in the IMM-101þGEM group and two
patients in the GEM group were lost to follow-up and censored at
the last allowed date of follow-up. Demographic and baseline
characteristics were mostly balanced between the treatment groups,
but with some differences observed for age distribution, gender, PS,
time since diagnosis, CA19.9 and NLR (Table 1). 84% of patients
had metastatic disease on enrolment.
Safety and exposure. The Safety population was the same as the
ITT population, except that one patient was excluded from the
IMM-101þGEM group, having been withdrawn before study drug
administration.
Median time on study was 4.83 months (range 0.2–12.0) for
IMM-101þGEM, and 2.79 months (0.5–10.9) for GEM. The total
time on study was 414 months for the IMM-101þGEM group and
133 months for the GEM group. Median duration of exposure to
GEM was longer for IMM-101þGEM compared to GEM (78 and
59 days, respectively). To assess the impact on toxicity of the longer
time on study observed for the IMM-101þGEM group, the rates
of patients per month on study reporting at least one AE or at least
one SAE were also calculated and are reported here.
Seventy three (99%) patients reported at least one AE in the
IMM-101þGEM group compared with 35 (100%) patients in the
GEM group. The corresponding rate of patients reporting at least
one AE per month on study for IMM-101þGEM vs GEM was
0.18 vs 0.26. Pyrexia occurred with the greatest difference in
incidence between IMM-101þGEM vs GEM (28.4% v 8.6%), with
all cases in the IMM-101þGEM group being grade 1 (majority) or
grade 2. Grade 3 and higher AEs occurred in 57 (77%) patients in
the IMM-101þGEM group and 26 (74%) patients in the GEM
group. All grade 3 and higher AEs with an incidence of X5% in
either group are shown in Table 2.
Percentages for reasons for withdrawal were calculated in relation to the total number of patients who 
discontinued treatment in each treatment arm
Assessed for eligibility
(n = 142)
Randomly assigned (n = 110)
Did not meet exclusion criteria
(n = 32)
IMM-101 and gemcitabine (n = 75) Gemcitabine alone (n = 35)
Received treatment (n = 74)
Did not receive treatment   (n = 1)
Received treatment (n = 35)
Did not receive treatment (n = 0)
Completed study (n = 12, 16%)
Treatment discontinued (n = 63, 84%)
Disease progression (n = 25, 40%)
Adverse event (n = 5, 8%)
Death (n = 20, 32%)
Consent withdrawn (n = 2, 3%)
Other (11, 17%)
Completed study (n = 1, 3%)
Treatment discontinued (n = 34, 97%)
Disease progression (n = 17, 50%)
Toxicity to Gem (n = 2, 6%)
Death (n = 7, 21%)
Consent withdrawn (n = 2, 6%)
Other (n = 6, 18%)
Figure 1. CONSORT diagram.
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Thirty six patients reported at least one SAE in the IMM-
101þGEM group compared to 10 patients in the GEM group.
The corresponding rate of patients reporting at least one SAE per
month on study for IMM-101þGEM vs GEM was 0.09 vs 0.08.
SAEs which occurred inX5% of IMM-101þGEM treated patients
were biliary sepsis, abdominal pain and pyrexia (each occurring in
5% of patients) and disease progression in the GEM group (6%).
The incidence of individual SAEs was low and no trend could be
observed.
Fatal (grade 5) AEs were reported in 19% of the IMM-101þ
GEM group vs 14% in GEM, although none were considered
related to study drug.
IMM-101 injection site reactions were almost all mild or
moderate with isolated severe reactions in 4% of patients who all
subsequently continued treatment. Only 2 patients (3%) required a
reduction to half dose as a result of local reactions, and both
completed the study. The worst impact of IMM-101 injection on
patients’ daily activities related to 8% reporting a moderate impact
which resolved during their time on study.
Treatment-related AEs leading to withdrawal from study were
reported in 5% of the IMM-101þGEM group (all but 1 event
related to GEM and two also related to IMM-101) vs none in GEM.
Efficacy. Survival analysis of the ITT group included deaths in
85% of the IMM-101þGEM group and 91% of the GEM group,
with median follow-up of 6.7 months (range 0.4–30.3) and 4.9
months (0.5–16.8), respectively. Table 3 and Figure 2 show the
results for median OS and PFS.
Median OS in the ITT population was 6.7 months for IMM-
101þGEM v 5.6 months for GEM (HR, 0.68; 95% CI, 0.44–1.04,
P¼ 0.074); the difference was not formally statistically significant.
28% of patients in the IMM-101þGEM group and 34% in the
GEM group took second-line therapy; 15 patients from the IMM-
101þGEM group continued to receive IMM-101.
Analysis of the predefined metastatic subgroup (n¼ 92) showed
a difference in survival between the treatment groups with median
survival for IMM-101þGEM of 7.0 vs 4.4 months for GEM
(HR, 0.54; 95% CI 0.33–0.87, P¼ 0.01). The smaller subgroup of
patients with locally advanced disease (n¼ 18) showed a lower
median survival for IMM-101þGEM of 6.7 months vs 9.2 months
for GEM (HR, 3.81; 95% CI 1.03–14.05, P¼ 0.032). Results are
difficult to interpret in the latter subgroup because of the low
number of patients.
The planned survival analysis based on PS (0–1 vs 2) was not
performed because the PS2 subgroup from the GEM arm
contained only thre patients.
Results for PFS reflected those for OS. In the ITT population,
median PFS was 4.1 months for IMM-101þGEM vs 2.4 months
for GEM (HR, 0.58; 95% CI 0.37–0.91; P¼ 0.016); the difference
was statistically significant. For the metastatic subgroup, median
PFS was 4.4 months for IMM-101þGEM vs 2.3 months for GEM
(HR 0.46; 95% CI 0.28–0.75; P¼ 0.001). The small subgroup with
locally advanced disease had median PFS of 3.4 months for IMM-
101þGEM vs 5.3 months for GEM (HR 2.38; 95% CI 0.65–8.78;
P¼ 0.177).
The exploratory multivariate analysis of PFS and OS outcomes
indicated that baseline CA19.9, CEA, CRP, NLR and randomised
treatment were prognostic for PFS outcome in the ITT population
and metastatic subgroup and also for OS outcome in the metastatic
subgroup. For OS in the ITT population, randomised treatment fell
marginally short of the multivariate stepwise inclusion criteria.
Overall, these exploratory analyses confirmed that the differences
seen for PFS and OS between IMM-101þGEM v GEM were not
attributable to important prognostic factors and any associated
chance baseline imbalances. An exploratory multivariate analysis
was not performed on the subgroup with locally advanced disease
because the number of patients was too small.
Table 1. Baseline characteristics of all enrolled patients
IMM-101þGEM
(n¼75) GEM (n¼35)
Age, years
Median 68 66
Range 45–88 53–83
Distribution, no (%)
p65 28 (37) 16 (46)
465 47 (63) 19 (54)
Sex, no (%)
Female 37 (49) 14 (40)
Male 38 (51) 21 (60)
Race, no (%)
White 74 (99) 33 (94)
Asian 1 (1) 0
Other 0 1 (3)
Unknown 0 1 (3)
ECOG performance status (PS), no (%)
0–1 62 (83) 32 (91)
2 13 (17) 3 (9)
Time since first diagnosis, months
Median 1.22 0.76
Range 0.1–6.9 0.1–3.9
Extent of disease, no (%)
Locally advanced 11 (15) 7 (20)
Metastatic 64 (85) 28 (80)
CA19.9, KU l1
Median 485.8 2747
Range 0.6–455, 480 0.1–100 000
Distribution, no (%)
p1000 38 (58) 11 (32)
41000 27 (42) 23 (68)
CEA, mg l1
Median 10 9.3
Range 0.7–679.9 2.0–681.0
Distribution, no (%)
p10 33 (51) 17 (55)
410 32 (49) 14 (45)
LDH, U l1
Median 198.5 221
Range 118–2101 145–643
Distribution, no (%)
p250 42 (66) 18 (60)
4250 22 (34) 12 (40)
CRP, mg l1
Median 10 11.9
Range 0.8–330.0 0.6–76.8
Distribution, no (%)
p10 37 (51) 16 (46)
410 35 (49) 19 (54)
Total bilirubin, mgdl1
Median 0.6 0.68
Range 0.24–4.40 0.24–2.04
Distribution, no (%)
p1 52 (69) 21 (62)
41 23 (31) 13 (38)
NLR
Median 3.42 3.91
Range 1.24–1518.52 0.53–9.11
Distribution, no (%)
p5 55 (73) 28 (80)
45 20 (27) 7 (20)
Abbreviations: CA19.9¼ carbohydrate antigen 19.9; CEA¼ carcinoembryonic antigen;
CRP¼C-reactive protein; ECOG¼Eastern Cooperative Oncology Group; GEM¼
gemcitabine; LDH¼ lactate dehydrogenase, NLR¼ neutrophil-lymphocyte ratio.
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The ORR of 10.7% was numerically higher for IMM-101þ
GEM (95% CI 4.7–19.9) v 2.9% for GEM (95% CI 0.1–14.9;
P¼ 0.164). The best overall response was a PR (i.e., there were no
complete responders).
The disease stabilisation rate was 44% (95% CI 32.5–55.9) for
IMM-101þGEM and 34.3% (95% CI 19.1–52.2, P¼ 0.334) for
GEM.
DISCUSSION
IMAGE-1 is the first, randomised, phase II, POC study to explore
the safety and tolerability of IMM-101 in combination with GEM
vs GEM alone as first-line treatment in advanced PDAC. IMM-
101þGEM was as well tolerated as GEM alone: the rates of
patients per month on study reporting at least one AE or at least
one SAE were similar between treatment groups.
Pyrexia is typical post-vaccination, and was more frequent in
the IMM-101þGEM group, with all cases classified as Grade 1 or
2. Injection–site reactions are a predictable reaction to mycobac-
terial antigens and were well tolerated by patients.
Grade 3 and higher AEs occurred at a similar incidence between
treatment arms. No treatment-related deaths occurred.
This POC study was not formally sized to test a specific efficacy
hypothesis, nonetheless, it has provided important insights into the
potential for efficacy improvements with the use of IMM-101 in
PDAC. For the overall ITT population, the median OS was similar
between treatment groups while PFS was greater in the IMM-
101þGEM group.
The pre-planned subgroup analysis of patients with locally
advanced disease contained only 16% of the ITT population;
Table 2. Grade 3 and higher adverse events occurring in at least 5% patients in either group
Number of patients (%)
NCI CTC adverse events IMM-101þGEM (n¼74) GEM (n¼35)
Difference in Incidence Rates
(IMM-101þGEM–GEM)
Asthenia 8 (11%) 1 (3%) 8%
Abdominal pain 6 (8%) 1 (3%) 5%
Vomiting 4 (5%) 0 5%
Anaemia 6 (8%) 1 (3%) 5%
Biliary sepsis 4 (5%) 0 5%
Bile duct obstruction 4 (5%) 1 (3%) 2%
Neutropenia and/or neutrophil count decreased 13 (18%) 6 (17%) 1%
Leukopenia and/or WBC count decreased 3 (4%) 4 (11%)  7%
Hypokalaemia and/or blood potassium decreased 0 2 (6%)  6%
Fatigue 4 (5%) 4 (11%)  6%
Urinary tract infection 1 (1%) 2 (6%)  5%
Disease progression 3 (4%) 3 (9%)  5%
Thrombocytopenia and/or platelet count decreased 5 (7%) 3 (9%)  2%
ALT increased 3 (4%) 2 (6%)  2%
Abbreviations: ALT¼ alanine transaminase; GEM¼gemcitabine; NCI CTC¼National Cancer Institute Common Terminology Criteria; WBC¼ white blood cells.
Table 3. Overall survival and progression-free survival
Median survival, months (95% CI)
IMM-101þGEM GEM
Hazard ratio
(95% CI)
Log rank
P-value
(two sided)
All patients 6.7 (5.4–7.5) (n¼ 75) 5.6 (3.2–7.2) (n¼ 35) 0.68 (0.44–1.04) 0.074
Metastatic subgroup 7.0 (5.5–9.0) (n¼ 64) 4.4 (2.8–6.5) (n¼ 28) 0.54 (0.33–0.87) 0.01
Locally advanced disease subgroup 6.7 (1.4–7.2) (n¼ 11) 9.2 (3.5–15.9) (n¼ 7) 3.81 (1.03–14.05) 0.032
Median progression-free survival,
months (95% CI)
IMM-101þGEM GEM
Hazard ratio
(95% CI)
Log rank
P-value
(two sided)
All patients 4.1 (3.3–4.8) (n¼75) 2.4 (2.1–4.0) (n¼35) 0.58 (0.37–0.91) 0.016
Metastatic subgroup 4.4 (3.3–5.1) (n¼64) 2.3 (1.9–2.8) (n¼28) 0.46 (0.28–0.75) 0.001
Locally advanced disease subgroup 3.4 (1.4–4.8) (n¼11) 5.3 (1.9–6.7) (n¼7) 2.38 (0.65–8.78) 0.177
Abbreviations: CI¼ confidence interval; GEM¼ gemcitabine.
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n¼ 11 for IMM-101þGEM and n¼ 7 for GEM with just 11 and 6
deaths, respectively. Consequently, analyses in locally advanced
patients lack robustness and are associated with wide CIs. In
contrast, the pre-planned subgroup analysis of patients with
metastatic disease contained 84% of the ITT population, and
therefore, provide more reliable evidence regarding the possible
effect of IMM-101þ GEM v GEM in this population. HRs and
median OS and PFS were higher in the IMM-101þGEM group,
and associated CIs were narrower so increasing the confidence of
the possibility of a true survival benefit in the IMM-101þGEM
group.
In a study of this size, with 2 : 1 randomisation, there is the
chance that any apparent treatment benefit may be due to an
imbalance in baseline characteristics, and some degree of
imbalance for certain factors was noted (Table 1). However, a
multivariate analysis based on factors reported as prognostic for
survival in the literature (Bilici, 2014; Haas et al, 2013), and for
which data were collected, showed, overall, that the differences
seen for PFS and OS between the IMM-101þGEM group vs GEM
were not attributable to important prognostic factors and any
associated chance baseline imbalances. Missing data from some
patients (maximum of 15% in IMM-101þGEM group and 14% in
the GEM group) may have influenced results. Data were not
collected on the site of primary tumour (head/body) which has
been shown to be prognostic in some studies, although without a
clear consensus (Bilici, 2014).
The median survival times for the GEM group were relatively
low compared with some published information for pancreatic
cancer patients receiving GEM monotherapy. The younger age
of the study population in recently published phase III studies
(58% oage 65 years in MPACT (Von Hoff et al, 2013) and 71%
page 65 years in FOLFIRINOX trial (Conroy et al, 2011)) may
have contributed to improved OS in those studies, although age
was not shown to be prognostic for survival in IMAGE-1 which
had 60% of patients aged over 65 years. Published median OS for
patients receiving GEM monotherapy shows considerable variation
from 4.9 months (Poplin et al, 2009) to 8.3 months (Colucci et al,
2010) (for predominantly metastatic populations). In a systematic
review, median survival for patients with pancreatic cancer who
underwent interventions (including chemotherapy, radiotherapy
or surgery) ranged from 2–8.1 months (Carrato et al, 2015).
In IMAGE-1, the relatively long time from diagnosis (Table 1) with
eligibility not restricted to newly diagnosed patients, may have
reduced median OS in both arms.
Upon disease progression or toxicity to GEM, the protocol
allowed treatment changes to be made on study, rather than only
after withdrawal. This facilitated data collection and allowed
patients from the IMM-101þGEM group to continue to receive
IMM-101. The use of second-line anticancer therapy was balanced
between treatment groups with 28% of patients in the IMM-
101þGEM group and 34% in the GEM group; this had no bearing
on the ITT analysis.
In this study, IMM-101 in combination with GEM was as safe
and well tolerated as GEM alone in patients with advanced PDAC,
and there was a suggestion of a beneficial effect on survival in
patients with metastatic disease. This supports further evaluation
of IMM-101 in an adequately powered confirmatory study.
Moreover, ongoing analyses to identify potentially predictive
markers of response will guide the design of this new study.
Currently there are 150 studies listed on https://clinicaltrials.-
gov/ that are investigating the combination of GEM with nab-
paclitaxel in different combination regimens for pancreatic cancer.
Where reported, the study populations are significantly younger
and clinically fitter than in IMAGE-1.
There are also several studies evaluating combinations with
FOLFIRINOX. While promising activity has been seen as judged
by response rate (Nywening et al, 2016), the toxicity of
FOLFIRINOX-based regimens precludes treatment of the majority
of patients with advanced pancreatic cancer.
The clinical crux is that GEM still represents the clinical option
for patients with poorer performance status in this disease. In
addition, single agent GEM still continues to be the standard of
care for patients who are not fit for FOLFIRINOX in economically
restricted health care systems globally. Therefore, our intention is
to plan a large, adequately powered, phase III study of IMM-101 in
combination with GEM for the first-line treatment of patients with
metastatic pancreatic cancer. The patient population that is eligible
for this study will be defined carefully to ensure that only those
patients who are not suitable for treatment with GEMþ nab-
paclitaxel or FOLFIRINOX are enroled.
We do acknowledge the need to investigate IMM-101 in
combination with standard of care in first-line treatment of
metastatic pancreatic cancer, and also in second-line treatment of
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Figure 2. Progression-free survival ITT Analysis Set (A) and ITT
Metastatic Subgroup (B). Overall survival Metastatic Subgroup (C).
Arrows denote censored events. IMM-101 treated: IMM-101þGEM;
Control: GEM alone.
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metastatic pancreatic cancer in combination with MM-398, a
nanoliposomal encapsulation of irinotecan,þ 5-fluorouracil and
folinic acid (Wang-Gillam et al, 2016). Therefore, a follow-up
phase I/IIa trial to evaluate the safety, tolerability and activity of
IMM-101 in combination with different chemotherapy regimens in
pancreatic cancer is currently being instigated.
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